Drugs / NeoTIL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04643574 | Mar 2021 → Nov 2027 expected | cancer | Centre Hospitalier Universitaire Vaudois | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NeoTIL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04643574 ↗ |
| Modality | Cell therapy | “Adoptive transfer of ex vivo expanded Autologous Tumor-Infiltrating Lymphocytes enriched for tumor antigen specificity (NeoTIL)” NCT04643574 ↗ |
| Route | Intravenous | “Patients will receive NeoTIL infusion intravenously” NCT04643574 ↗ |